CMS Awards Monteris Add-On Payment For Tumor Ablation Catheter
This article was originally published in The Gray Sheet
Executive Summary
Monteris Medical expects to deploy its AutoLITT tumor ablation catheter to the market "slowly and methodically" following a favorable Medicare reimbursement decision, according to Jim Duncan, the firm's CEO
You may also be interested in...
Cook’s Zenith Fenestrated AAA Graft Nets Positive Payment Rulings In Medicare Reg
The firm’s specialized endovascular abdominal aortic aneurysm product was the only device newly awarded a new-technology add-on payment for fiscal 2013, and was moved to a higher-paying procedure category than CMS had previously proposed.
People In Brief
Monteris Medical gets a new CEO. Zeltiq's chief executive resigns. More moves by movers and shakers in the medical device and diagnostics industries.
CMS In Brief
Proposed rulemaking limits MRI coverage for pacemaker/defibrillator patients